Oncobiologics was ranked as the fifth worst IPO this year, generating negative returns of 30.3 percent. The developer of biosimilars of blockbuster drugs Humira and Avastin, raised $35 million by offering 5.8 million shares at $6 per share. Listed on the Nasdaq Global Market under the symbol “ONS”, the company had previously filed to offer 5 million shares at a range of $11 to $13 per share.